SA.41471(2015/X) Purpose_public_aid: Article 25 of Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in application of Articles 107 and 108 of the Treaty (OJ Urz. EU L 187/1 of 26.06.2014).Immunooncology revolutionised the approach to cancer therapy. It responds to an unfulfilled therapeutic need for the treatment of aggressive cancers for which current therapies are ineffective. Activation of the patient’s immune system uses signal pathways that support the diagnosis of cancer cells, the mobilisation of immune cells with anti-cancer action, and the removal of immunosuppressive mechanisms of the tumor. This leads to selective eradication of cancer, saving healthy tissues and creating long-term immune memory to prevent relapse and metastasis giving the effect of an anticancer vaccine. Clinical data confirm the effectiveness of immunotherapy and long-term therapeutic effect. The aim of the project is to implement into the activities of Ryvu Therapeutics S.A. a candidate characterised in the first clinical phase for a drug that overcomes the limitations of current immunotherapy. It provides an opportunity for effective and safe treatment of patients with aggressive, resistant tumours as monotherapy or in combination with other immuno therapies or standard therapeutic options. The proposed strategy involves working on two protein targets in the preclinical phase: HPK1 (MAP4K1) and IRAK3 (IRAK-M) to increase the chance of selecting a clinical candidate with the greatest therapeutic potential and therefore the greatest chances of success in clinical trials and commercialisation. The result will be a small-molecular modulator of the patient’s immune response against his own cancer cells as a strictly personalised therapy. The developed leading compounds, which have the chance to become a first-in-class drug, will be pharmacodynamically characterised and (...)